DVAX logo

DVAX
Dynavax Technologies Corp.

18,866
Mkt Cap
$1.22B
Volume
507,887.00
52W High
$14.63
52W Low
$9.20
PE Ratio
-21.87
DVAX Fundamentals
Price
$10.44
Prev Close
$10.38
Open
$10.41
50D MA
$10.04
Beta
0.74
Avg. Volume
1.89M
EPS (Annual)
$0.2048
P/B
2.46
Rev/Employee
$684,558.03
Loading...
Loading...
News
all
press releases
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025...
PR Newswire·5d ago
News Placeholder
More News
News Placeholder
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial Dynavax Presents Positive Topline Data...
PR Newswire·6d ago
News Placeholder
Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday
The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.
Stocktwits·2mo ago
News Placeholder
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Exelixis (EXEL) Beats Q2 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
chainwire·6mo ago
News Placeholder
Dynavax to Participate in Upcoming Investor Conferences
Dynavax to Participate in Upcoming Investor Conferences Dynavax to Participate in Upcoming Investor Conferences PR Newswire EMERYVILLE, Calif., Feb. 25, 2025 EMERYVILLE, Calif., Feb. 25, 2025...
PR Newswire·8mo ago
News Placeholder
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides...
PR Newswire·8mo ago

Latest DVAX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.